Arpeggio Bio is a preclinical stage drug discovery company using nascent RNA sequencing and machine learning to find new target therapeutic targets and biomarkers for hard to treat cancers. Our platform discovered a new biomarker for Ferroptosis, a non-canonical form of cell death that can be selectively activated in sarcomas. With our biomarker, we identified a lead compound with high potency and selectivity for Sarcomas and are looking to partner on IND-enabling studies.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):